Understand the source comparison
The Pivotal Comparisons
A Phase II trial published in Fertility and Sterility (registered as ClinicalTrials.gov NCT01270841) compared oral enclomiphene against 1% topical testosterone gel in men with secondary hypogonadism, again finding that enclomiphene increased morning serum test
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- A Phase II trial published in Fertility and Sterility (registered as ClinicalTrials.gov NCT01270841) compared oral enclomiphene against 1% topical testosterone gel in men with secondary hypogonadism, again finding that enclomiphene increased morning serum testosterone, estradiol, and LH to levels comparable with the gel, while increasing FSH and LH and conserving sperm counts — reversing the biochemical hallmarks of the condition while preserving spermatogenesis.[3][13] The accompanying editorial commentary in the same journal placed these results in the broader context of using SERMs for male hypogonadism and infertility.[11]
- The largest and most rigorous data came from two parallel randomized, double-blind, double-dummy, placebo-controlled, multicenter Phase III studies (designated ZA-304 and ZA-305). These enrolled overweight men aged 18–60 with secondary hypogonadism — morning total testosterone at or below 300 ng/dL and low or normal LH — and evaluated two enclomiphene doses against testosterone gel over 16 weeks.[4] The results reproduced the earlier pattern at scale: total testosterone rose across all active groups, but FSH and LH increased with enclomiphene and decreased with the gel, and enclomiphene maintained sperm concentration in the normal range while the testosterone-gel group showed a marked reduction in spermatogenesis.[4] The authors summarized the contrast with the memorable phrase “restoration instead of replacement.”
- A methodological detail explains why these Phase III studies carry the most weight in the whole enclomiphene record. Because an oral capsule and a topical gel cannot be blinded to one another by appearance, the trials used a double-dummy design, in which every participant received both a capsule and a gel — one active and one matching placebo — so that neither investigators nor subjects could infer the treatment assignment from the dosage form.[4] That rigor is exactly what makes the divergent gonadotropin and sperm findings hard to dismiss as an artifact of unblinding, even though the program still did not convert this evidence into a regulatory approval.
- Kaminetsky 2013[1]
- Phase IIB, open-label, n=12
- Secondary hypogonadism, prior gel users
- Enclomiphene raised LH/FSH and sperm counts; gel did not
- Wiehle 2013[2]
- Phase II PD/PK, n=48
- Men with secondary hypogonadism
- Dose-related TT rise; LH/FSH up vs. gel suppression
- Wiehle 2014[3]
- Phase II RCT vs. topical T
- Secondary hypogonadism
- Reversed low TT + low LH; sperm counts conserved
- Kim 2016[4]
- Phase III, double-blind (ZA-304/305)
- Overweight men, TT ≤300 ng/dL
- TT restored; sperm preserved with enclomiphene, reduced with gel